Ricardo Solano Authors Article on Implications of Corporate Integrity Agreements

Ricardo Solano, Jr.
Pharmaceutical Compliance Monitor
April 13, 2016

Friedman Kaplan partner Ricardo Solano, Jr. has published an article in Pharmaceutical Compliance Monitor addressing the implications and requirements for success that corporate health care providers should expect should they enter into corporate integrity agreements.

For corporate health care providers involved in a civil health care fraud investigation, entering into a corporate integrity agreement (CIA) with the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) is often a necessary condition to resolving the matter.  If there is a parallel criminal investigation, CIAs are usually, although not necessarily, included as part of any global resolution.  A discussion of what providers should expect from these agreements and tips for ensuring success can be found in the full article, available here.

View Document(s):

Attorneys